KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash & Equivalents (2016 - 2026)

Idexx Laboratories has reported Cash & Equivalents over the past 17 years, most recently at $180.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 37.53% year-over-year to $180.1 million; the TTM value through Dec 2025 reached $180.1 million, down 37.53%, while the annual FY2025 figure was $180.1 million, 37.53% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $180.1 million at Idexx Laboratories, down from $208.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $453.9 million in Q4 2023 and troughed at $99.2 million in Q3 2022.
  • A 5-year average of $227.3 million and a median of $192.3 million in 2022 define the central range for Cash & Equivalents.
  • On a YoY basis, Cash & Equivalents climbed as much as 331.43% in 2021 and fell as far as 62.37% in 2021.
  • Year by year, Cash & Equivalents stood at $144.5 million in 2021, then fell by 22.09% to $112.5 million in 2022, then skyrocketed by 303.33% to $453.9 million in 2023, then crashed by 36.5% to $288.3 million in 2024, then crashed by 37.53% to $180.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for IDXX at $180.1 million in Q4 2025, $208.2 million in Q3 2025, and $164.6 million in Q2 2025.